ArticleSaudi journal of biological sciences2022
The role of serotonergic and catecholaminergic systems for possible antidepressant activity of apigenin.
Article in Saudi journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis.Pharmaceutical biology · 2025Pooled it
- Therapeutic potential of apigenin in neurodegenerative diseases and brain health.Molecular biology reports · 2026Review
- Comparison of Selected Pro-Health Biologically Active Chemical Compounds inMolecules (Basel, Switzerland) · 2026Article
- The Efficacy of Combination Therapy With SWTX Capsule and Paroxetine for Depression: A Randomized Controlled Trial.Health science reports · 2026Article
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Coumarin benzamide scaffold as potential 5-HTJournal of molecular modeling · 2025Article
- Investigation of Anticonvulsant Potential ofInternational journal of molecular sciences · 2025Article
- A Deep Dive into the Botanical and Medicinal Heritage ofPlants (Basel, Switzerland) · 2025Review
- Phytoconstituents Targeting the Serotonin 5-HTACS pharmacology & translational science · 2024Review
- The Beneficial Role of Apigenin against Cognitive and Neurobehavioural Dysfunction: A Systematic Review of Preclinical Investigations.Biomedicines · 2024Review
- Flavonoid Components, Distribution, and Biological Activities inMolecules (Basel, Switzerland) · 2023Review
- Potential Antioxidant Activity of Apigenin in the Obviating Stress-Mediated Depressive Symptoms of Experimental Mice.Molecules (Basel, Switzerland) · 2022Article
- Participation of the Serotonergic System and Brain-Derived Neurotrophic Factor in the Antidepressant-like Effect of Flavonoids.International journal of molecular sciences · 2022Review
- Plumbagin Alleviates Intracerebroventricular-Quinolinic Acid Induced Depression-like Behavior and Memory Deficits in Wistar Rats.Molecules (Basel, Switzerland) · 2022Article
- Apigenin for Depression and Anxiety: A Systematic Review of Preclinical Studies.Iranian journal of pharmaceutical research : IJPRReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAlthough, the anti-depressant like effects of apigenin (APG) are documented in the literature, the underlying mechanism for exerting such an effect is still not clear. In this research, an attempt was made to determine the possible role of APG for antidepressant activity through serotonergic and catecholaminergic systems using standardized animal models. MATERIALS AND
methodsThe antidepressant property of APG was determine by involving tail suspension (TST) and modified forced swimming tests (MFST). The effect of APG was evaluated at 25 and 50 mg/kg. In mechanistic models, animals were pretreated with catecholaminergic and serotonergic antagonists prior to administration of APG. The results obtained were statistically analyzed to determine the level of significance.
resultsThe period of immobility in both models (TST and MFST) was significantly reduced by APG (25 and 50 mg/kg). The best therapetuic dose of APG (50 mg/kg) was selected for the mechanistic study. The anti-immobility effect of APG declined to a significant extent upon pretreatment with catecholaminergic antagonists (α-methyl-para-tyrosine methyl ester; SCH 23390; sulpiride; phentolamine) and serotonergic inhibitors (
conclusionsThe findings suggest that APG's antidepressant effect is mediated by the α-adrenergic, dopaminergic and 5-HT3 serotonergic receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.